PTC Therapeutics is transitioning from a period of erratic revenue and negative margins toward a more sustainable operating profile, as evidenced by the 2026Q2 operating margin of 41.3% on $360.5M revenue. The company's asset-light model (capex under 2% of rev...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth of 101.5% year-over-year in 2026Q2 drove a 41.3% operating margin, a stark improvement from the -49.6% margin in 2025Q4, though gross margin instability (45.1% in 2025Q3 vs. 85.5% in 2026Q1) suggests mix shifts.
PTC Therapeutics issued full-year 2026 guidance projecting total product revenue of US$700 million to US$800 million, excluding Evrysdi royalty and collaboration revenue.
PTC Therapeutics reported positive 24-month interim results from the PIVOT-HD study, showing dose-dependent slowing of Huntington's disease progression and sustained reduction of mutant Huntingtin protein with votoplam.
An investment manager significantly increased their position in PTCT stock, adding 41,000 shares, as indicated by a recent SEC filing.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.92+289.3% vs $0.24 | $361M+20.7% vs $299M |
Q2 2026 May 7, 2026 | -$0.03+93.3% vs -$0.45 | $273M+25.4% vs $217M |
Q1 2026 Feb 19, 2026 | -$1.67-695.2% vs -$0.21 | $165M-41.1% vs $279M |
Q4 2025 Nov 4, 2025 | $0.20+116.8% vs -$1.19 | $211M-25.0% vs $281M |
– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease.
PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Amundi grew its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 171.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,227 shares of the biopharmaceutical company's stock after acquiring an additional 7,727 shares during
California State Teachers Retirement System raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 7,806.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,666,961 shares of the biopharmaceutical company's stock after buying
Benchmark PTCT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for PTC Therapeutics, Inc. (PTCT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $62.34 | $5.17B | 8.01 | 114.51% | 39.44% | — | — | |
| $18.95 | $2B | -2.66 | 15.58% | -6.93% | -9.96% | — | |
| $62.21 | $12.02B | 34.56 | 12.87% | 2.14% | 1.18% | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — | |
| $246.51 | $32.91B | 105.80 | 65.19% | 16.82% | 93.61% | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — |
PTC Therapeutics, Inc. (PTCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
PTC Therapeutics, Inc. (PTCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 18, 2026·SEC
Jun 16, 2026·SEC
Get notified when PTCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PTC Therapeutics, Inc. (PTCT) stock FAQ — growth, dividends, profitability & financials explained
PTC Therapeutics, Inc. (PTCT) reported $1.01B in revenue for fiscal year 2025. This represents a 919% increase from $99.0M in 2011.
PTC Therapeutics, Inc. (PTCT) grew revenue by 114.5% over the past year. This is strong growth.
PTC Therapeutics, Inc. (PTCT) reported a net loss of $38.4M for fiscal year 2025.
PTC Therapeutics, Inc. (PTCT) had negative free cash flow of $74.6M in fiscal year 2025, likely due to heavy capital investments.
